Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (301-310 of 688) with videos related to

Pageof 69
Sort By:
Journal of the American Heart Association|January 6, 2018
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive PatientsRobert D Brook, Niko Kaciroti, George Bakris, et al.
The American Journal of Medicine|August 12, 2019
Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment TrialPhillip H Lam, Milton Packer, Gregg C Fonarow, et al.
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
American Journal of Hypertension|September 15, 2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionKenneth A Jamerson, George L Bakris, Chuan-Chuan Wun, et al.
European Heart Journal. Acute Cardiovascular Care|September 28, 2018
Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarctionXavier Rossello, João Pedro Ferreira, John Jv McMurray, et al.
Journal of the American College of Cardiology|May 11, 2019
Estimated Long-Term Survival With EplerenoneSusan Stienen, João Pedro Ferreira, John Vincent, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenoneRajiv Agarwal, Stefan D Anker, George Bakris, et al.
European Journal of Heart Failure|October 14, 2015
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitorsBertram Pitt, George L Bakris, David A Bushinsky, et al.
The American Journal of Medicine|November 29, 2017
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS InhibitorsMatthew R Weir, David A Bushinsky, Wade W Benton, et al.
Pharmacoeconomics|September 9, 2018
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with HyperkalemiaMark Bounthavong, Javed Butler, Chantal M Dolan, et al.
Pageof 69

Showing results (301-310 of 688) with videos related to

Sort By:
Pageof 69
Journal of the American Heart Association|January 6, 2018
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive PatientsRobert D Brook, Niko Kaciroti, George Bakris, et al.
The American Journal of Medicine|August 12, 2019
Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment TrialPhillip H Lam, Milton Packer, Gregg C Fonarow, et al.
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
American Journal of Hypertension|September 15, 2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionKenneth A Jamerson, George L Bakris, Chuan-Chuan Wun, et al.
European Heart Journal. Acute Cardiovascular Care|September 28, 2018
Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarctionXavier Rossello, João Pedro Ferreira, John Jv McMurray, et al.
Journal of the American College of Cardiology|May 11, 2019
Estimated Long-Term Survival With EplerenoneSusan Stienen, João Pedro Ferreira, John Vincent, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenoneRajiv Agarwal, Stefan D Anker, George Bakris, et al.
European Journal of Heart Failure|October 14, 2015
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitorsBertram Pitt, George L Bakris, David A Bushinsky, et al.
The American Journal of Medicine|November 29, 2017
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS InhibitorsMatthew R Weir, David A Bushinsky, Wade W Benton, et al.
Pharmacoeconomics|September 9, 2018
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with HyperkalemiaMark Bounthavong, Javed Butler, Chantal M Dolan, et al.
Pageof 69